{"prompt": "['Study treatment', 'Safety Run-in phase', '1st step: Administered in 5 patients', 'FOLFIRI plus durvalumab', '- Durvalumab: 1500 mg by 1-hour IV infusion.', 'Every 4 weeks until progression', '- FOLFIRI (1 course every 2 weeks, until progression):', '- Irinotecan: 180 mg/m\u00b2 by 2-hour IV infusion,', '- Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion,', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus,', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hour IV infusion', '2nd step: Administered in 6 patients (3 patients per arm)', 'FOLFIRI plus durvalumab', '- Durvalumab: 1500 mg by 1-hour IV infusion.', 'Every 4 weeks until progression', '- FOLFIRI (1 course every 2 weeks, until progression):', '- Irinotecan: 180 mg/m\u00b2 by 2-hour IV infusion,', '- Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion,', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus,', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hour IV infusion', 'FOLFIRI plus durvalumab plus tremelimumab', 'Induction treatment: 4 cycles (i.e. 1 course every 4 weeks)', '- Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.', '- Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).', '- FOLFIRI (1 course every 2 weeks, until progression):', '- Irinotecan: 150 mg/m\u00b2 by 2-hour IV infusion', '-', 'Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hour IV infusion', 'Tremelimumab is administered for 4 courses (4 months) and then patient will continue to', 'receive FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus durvalumab and', 'disease control, tremelimumab can be re-introduced at investigator discretion.', 'Patient must have 2 weeks of washout period of first-line treatment before receiving the', 'treatment in the trial. Treatment will be repeated every 4 weeks until disease progression,', \"unacceptable toxicity or patient's refusal.\", 'All drugs (irinotecan, folinic acid and 5-FU) except durvalumab and tremelimumab will be', 'used in the context of their marketed authorization or recommendations (Th\u00e9saurus National', 'de Canc\u00e9rologie Digestive (www.tncd.org)) in France. Thus, durvalumab and tremelimumab', 'will be provided in this clinical trial. A pharmacovigilance follow-up will be implemented', 'during the study.', 'Phase II:', 'Arm A: FOLFIRI plus durvalumab', '- Durvalumab: 1500 mg by 1-hour IV infusion.', 'Every 4 weeks until progression', '- FOLFIRI (1 course every 2 weeks, until progression):', '- Irinotecan: 180 mg/m\u00b2 by 2-hour IV infusion,', '-', 'Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion,', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus,', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hour IV infusion', 'Arm B: FOLFIRI plus durvalumab plus tremelimumab', 'Induction treatment: 4 cycles (i.e. 1 course every 4 weeks)', '- Durvalumab: 1500 mg by 1-hour IV infusion - Every 4 weeks.', '- Tremelimumab: 75 mg by 1-hour IV infusion - Every 4 weeks (for only 4 cycles).', '- FOLFIRI (1 course every 2 weeks, until progression):', '- Irinotecan: 180 mg/m\u00b2 by 2-hour IV infusion', '- Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hour IV infusion', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 10 de 123']['In arm B: tremelimumab is administered for 4 courses (4 months) and then patient will', 'continue to receive FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus', 'durvalumab and disease control, tremelimumab can be re-introduce at investigator discretion.', 'Patient must have 2 weeks of washout period of first-line treatment before receiving the', 'treatment in the trial. Treatment will be repeated every 4 weeks until disease progression,', \"unacceptable toxicity or patient's refusal.\", 'All drugs (irinotecan, folinic acid and 5-FU) except durvalumab and tremelimumab will be', 'used in the context of their marketed authorization or recommendations (Th\u00e9saurus National', 'de Canc\u00e9rologie Digestive (www.tncd.org)) in France. Thus, durvalumab and tremelimumab', 'will be provided in this clinical trial. A pharmacovigilance follow-up will be implemented', 'during the study.', 'Safety analysis', 'For safety run-in phases, patients will be treated in 5 expert centers with a huge experience in', 'the use of immune checkpoints inhibitors.', '1st step: In order to check the good tolerability of FOLFIRI plus durvalumab combination, 5', 'patients will be treated by FOLFIRI (irinotecan 180mg/m\u00b2) plus durvalumab (1500 mg) in', '5', 'expert centers. The inclusion will be stopped at 5 patients. When the 5th patient will have', 'received 2 cycles of treatment, the safety analysis will be done with all the safety data', 'available at this date. The review will be done by an Independent Data Monitoring', 'Committee (IDMC).', 'The decision of IDMC and the data available will be sent to ANSM. We will wait the ANSM', 'approval to re-open the inclusion of patients.', '2nd step: 3 patients per arm will be randomized to receive either FOLFIRI (irinotecan 180', 'mg/m\u00b2) plus durvalumab (1500 mg) or FOLFIRI (irinotecan 150 mg/m\u00b2) plus durvalumab', '(1500 mg) plus tremelimumab (75 mg). These 6 patients will be treated in the same 5 expert', 'centers. When the 6th patient will have received 2 cycles of treatment, the safety analysis will', 'be done with all the safety data available at this date (for the 11 patients included in these', 'safety run-in phases). The review will be done by an Independent Data Monitoring', 'Committee (IDMC).', 'The decision of IDMC and the data available will be sent to ANSM. We will wait the ANSM', 'approval to open the phase II trial.', 'Randomization', 'The safety run-in will be done for the first step on an open-labeled part on 5 patients. A', 'simple enrollment process will be performed for the first step of safety run-in.', 'For the second step of safety run-in (3 patients per arm) and the phase II, the same', 'randomization process will be performed as described hereinafter.', 'The randomization will be done using minimization technique according to the ratio 1:1 and', 'the following factors will be considered for the stratification:', 'Center', '-', 'Duration of disease control with previous first-line chemotherapy (no disease control', 'VS < 3 months VS > 3 months)', 'Sample size calculation', 'No statistical hypotheses for the safety run-in phases. A total of 11 patients will be included', 'in the 2 steps before the randomized phase II will begin.', 'The clinical hypotheses for the randomized phase II study are:', '- H0: 50% of patients alive and without progression at 4 months is not acceptable.', '- H1: 70% of patients alive and without progression at 4 months is expected.', 'With a risk a (one-sided) of 5%, a power of 85% and according to the binomial-exact', 'design, 44 evaluable patients are needed by arms (i.e. patients randomized and with at least', 'one dose of products taken). Assuming 5% of non-evaluable patients or lost to follow-up, 47', 'patients will be included by arms (94 patients in total).', 'Taking into account the 11 patients included in the safety run-in phases, 105 patients will', 'be included in the trial.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 11 de 123']\n\n###\n\n", "completion": "END"}